Boston Trust Walden Corp boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 794.1% in the 3rd quarter, Holdings Channel reports. The firm owned 10,667 shares of the biopharmaceutical company’s stock after acquiring an additional 9,474 shares during the quarter. Boston Trust Walden Corp’s holdings in Regeneron Pharmaceuticals were worth $8,088,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the stock. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Armstrong Advisory Group Inc. increased its holdings in Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.
Insider Buying and Selling
In related news, Director Christine Poon sold 7,830 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the sale, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. This represents a 60.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the sale, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 28,228 shares of company stock worth $25,985,950 over the last ninety days. Corporate insiders own 6.97% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a report on Monday, November 2nd. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Monday, November 2nd. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $898.97.
Read Our Latest Report on REGN
Regeneron Pharmaceuticals Stock Performance
Regeneron Pharmaceuticals stock opened at $904.35 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. The stock has a market cap of $93.11 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10. The firm’s fifty day moving average price is $804.38 and its 200-day moving average price is $742.81.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.83 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.
The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Founded in 1988, Regeneron is headquartered in Tarrytown, New York.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
